Results 91 to 100 of about 30,153 (204)

Treatment of endometriosis by aromatase inhibitors: efficacy and side effects

, 2010
The recent demonstration that aromatase is expressed at higher levels in endometriosis implants than in normal endometrium has led to pilot studies using inhibitor aromatasis in patients with endometriosis.
Hoppé, Emmanuel, Legrand, Erick, Catala, Laurent, A.C. Racine, Sentilhes, Loic, E. Legrand, L. Catala, Lefebvre-Lacoeuille, Céline, C. Lefebvre-Lacoeuille, P. Descamps, Descamps, Philippe, E. Hoppé, L. Sentilhes, Racine, A-C   +13 more
core   +1 more source

EVALUASI MASKULINISASI PLATI PEDANG, Xiphophorus helleri MENGGUNAKAN KOMBINASI EKSTRAK BUAH PINUS, Pinus merkusii DENGAN AROMATASE INHIBITOR

Hormon 17α-methyltestostrone sudah banyak digunakan untuk maskulinisasi pada kegiatan budidaya namun, bahan tersebut bersifat karsinogenik sehingga diperlukan alternatif pengganti bahan tersebut.
Soelistyowati, Dinar Tri, Akbar, Muhamad Saepul, Sudrajat, Agus Oman, Arfah, Harton   +3 more
core   +1 more source

A synergistic suppression of aromatase by letrozole and the DAC inhibitor panobinostat (LBH589), an inhibitory modulator of aromatase gene expression.

, 2009
Abstract #3062 Background. The human aromatase gene contains nine translated exons (II-X) and at least eight tissue specific untranslated exon Is (I.1, I.2, I.3, I.4, I.5, I.6, I.7 and PII).
J Ye, DB Evans, I Kijima, S Chen
core   +1 more source

Comparative study of the efficacy of tamoxifen and aromatase inhibitors among breast cancer patients at Kenyatta National Hospital

Journal of the Egyptian National Cancer Institute
Background Aromatase inhibitors have demonstrated superior outcomes compared to tamoxifen in various studies. However, research in Africa, including Kenya, where breast cancer mortality rates are disproportionately high, is lacking.
Henry Gachoki Macharia, Amsalu Degu
doaj   +1 more source

When to start an aromatase inhibitor: Now or later?

, 2011
Among women who have undergone surgery for breast cancer, the risk of recurrence, especially distant metastases, peaks 1-2 years postsurgery. Recent clinical trial evidence suggests that initial adjuvant therapy with an aromatase inhibitor (AI) can ...
Julie C. Doughty, Doughty, J.C.
core   +1 more source

Panorama actual de los inhibidores de la aromatasa en la inducción de la ovulación Current view of aromatase inhibitors in ovulation induction

Revista Colombiana de Obstetricia y Ginecología, 2007
El panorama actual de la inducción de la ovulación en el tratamiento de la infertilidad está cambiando debido a la introducción reciente en este campo de los inhibidores de la aromatasa de tercera generación (IA).
Natalia Posada-Villa, Juan de Jesús Pachón-Rincón   +1 more
doaj  

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy

, 2016
Purpose: Aromatase inhibitors can exert unfavorable effects on lipid profiles; however, previous studies have reported inconsistent results. We describe the association of single-nucleotide polymorphisms (SNP) in candidate genes with lipid profiles in ...
Rae, James M., Skaar, Todd C., Ouyang, Pamela, Santa-Maria, Cesar A., Oesterreich, Steffi, Blackford, Amanda, Storniolo, Anna M., Philips, Santosh, Hayes, Daniel F., Nguyen, Anne T., Stearns, Vered, Robarge, Jason, Flockhart, David A., Henry, Norah Lynn, Blumenthal, Roger S., Post, Wendy S., Desta, Zeruesenay   +16 more
core   +1 more source

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report

Gynecologic Oncology Reports
Background: Treatment of recurrent chemotherapy, aromatase (AI) and MEK Inhibitor (MEKi) resistant low grade serous ovarian cancer (LGSOC) remains a challenge. Novel treatment options for KRAS mutated MEKi resistant LGSOC are warranted.
Victoria M. Ettorre, Luca Palmieri, Sarah Ottum, Michelle Greenman, Alessandro D. Santin   +4 more
doaj   +1 more source

Dual aromatase-steroid sulfatase inhibitors

, 2007
By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82
Chander, S.K., Purohit, A., Mahon, M.F., Bubert, C., Smith, A., Potter, B.V.L., Reed, M.J., Sutcliffe, O.B., Woo, L.W.L.   +8 more
core   +1 more source

Dual Aromatase−Steroid Sulfatase Inhibitors

, 2016
By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase−sulfatase inhibitors (DASIs) were generated. The best DASIs in vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82
Christian Bubert (2225098), L. W. Lawrence Woo (2225101), Mary F. Mahon (1293876), Michael J. Reed (494088), Atul Purohit (1064), Oliver B. Sutcliffe (1283655), Surinder K. Chander (2312797), Andrew Smith (11197), Barry V. L. Potter (286876)   +8 more
core   +1 more source